The impact of anti-commercial bribery shows that many pharmaceutical companies' quarterly reports are "injured"

As of October 30, 145 pharmaceutical companies in A-share listed companies have published the third quarter report of 2013, many of which failed to meet market expectations, resulting in the continued "sell-off" of the entire pharmaceutical sector The reporter of Shanghai Stock Exchange learned in the interview that the anti commercial bribery incident launched at the beginning of the third quarter of this year had a significant impact on pharmaceutical listed companies Since the third quarter, even normal academic promotion activities can no longer be held, and the company's market sales will inevitably be affected, the Secretary of a listed pharmaceutical company in Beijing told the Shanghai Stock Exchange However, since October, the impact of anti commercial bribery has gradually become smaller, and by the end of this year or the beginning of next year, business operation is expected to pick up The growth of the whole industry has been frustrated According to the third quarterly report of pharmaceutical enterprises, there are many companies whose performance is not as good as expected For example, Haizheng pharmaceutical realized a net profit of 54.37 million yuan in the third quarter, down 29.5% year-on-year, which was not as good as the performance of 28% increase in non net profit reported in the half year; huabangyingtai, which was frequently acquired, had an increase of 18% in the first three quarters, but a decrease of 16% in net profit year-on-year; Jiuan medical, a concept stock of wearable equipment, had a decrease of 28% in net profit when its income increased by 40%; biopharmaceutical The third quarter report of Watson bio showed that net profit fell 76.38% year on year In the opinion of researchers in the securities industry of Societe Generale, the main reason why the third quarter report of pharmaceutical listed companies is less than expected is due to the influence of anti commercial bribery investigation "It has a certain impact on the third quarter report of some prescription drug enterprises with high sales share of top three hospitals, for example, the growth rate of chemical enterprises is generally not fast, and the growth rate of the whole industry is slowing down in the third quarter." According to Niu Zhengqian, vice president of China Pharmaceutical Enterprise Management Association, the impact of the anti commercial bribery investigation on the industry began to show gradually from August, and the pharmaceutical enterprises were more cautious in their operation However, after entering the fourth quarter, the business began to recover slowly Focus on unaffected companies in this context, "smart healthcare" and private hospitals, which have nothing to do with commercial bribery and are in line with the direction of national medical reform, will become the main investment line of the pharmaceutical industry For example, Jinling Pharmaceutical Co., Ltd., the earliest private hospital investor, published the third quarter report, showing that the net profit after deducting non profits increased by 18.64%; the net profit after deducting non profits in the first three quarters of Kaiyuan investment was 120 million yuan, an increase of 41.24% The company's personage introduced to the reporter that the company will increase its investment in private hospitals, and will invest 330 million yuan to establish Xi'an Shengan hospital, further expand its business scale, and improve its market in the medical industry Field competitiveness In addition, it is worth noting that recently the State Council issued the guidance of "health service industry" to plan a blueprint of 8 trillion yuan for the industry; at the same time, the central government allocated 2.22 billion yuan to boost the large health industry, which has opened a new development space for listed companies such as Neusoft group and Weining software, which have been committed to the development of medical informatization for many years "This round of anti commercial bribery investigation is mainly aimed at foreign pharmaceutical giants, which means the end of the era of super national treatment of their foreign original research drugs in China With the continuous improvement of quality and technology, Chinese pharmaceutical enterprises are expected to take part in the foreign pharmaceutical market " Niu Zhengqian is optimistic about the development prospect of Listed Companies in China According to the reporter, Hengrui pharmaceutical, Huahai pharmaceutical, Qianjin pharmaceutical, Changshan pharmaceutical and other companies have more market opportunities in the third quarter of this year In the fourth quarter, these new market shares are expected to contribute to the growth of the company's performance.